- Home
- BMN vs BNR Comparison
BMN vs BNR Comparison
Compare BMN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMN | BNR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 126.5M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BMN | BNR |
|---|---|---|
| Price | $21.71 | $16.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.4K | ★ 59.8K |
| Earning Date | 01-01-0001 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $101.46 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.70 | $6.79 |
| 52 Week High | $27.96 | $41.72 |
Technical Indicators
Market Signals| Indicator | BMN | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 24.15 | 57.06 |
| Support Level | N/A | $15.61 |
| Resistance Level | $26.39 | $19.10 |
| Average True Range (ATR) | 0.76 | 1.76 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 13.68 | 56.24 |
Price Performance
Historical ComparisonAbout BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.